Depression Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The depression screening market size is expected to increase from USD 1.95 billion in 2025 to USD 2.10 billion in 2026 and reach USD 3.03 billion by 2031, growing at a CAGR of 7.62% over 2026-2031. This report is Segmented by Platform and Technology (Mobile Health Applications, Web-Based Screening Platforms, and More), Application (Clinical Screening and Diagnosis Support and More), Care Setting (Hospitals and Clinics, Primary Care Practices, and More), Age Group (Children, Adolescents, Adults), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Depression Screening Market Trends and Insights

Universal Screening Mandates Redefining Baseline Clinical Demand

Clinical recommendations are making depression screening a routine requirement rather than a discretionary service. The U.S. Preventive Services Task Force gave a Grade B recommendation for screening adults, including pregnant and postpartum people, in 2023. The task force also recommended screening adolescents aged 12 to 18. These recommendations support coverage without patient cost sharing under the Affordable Care Act when the service is delivered within the applicable requirements. This expands the billable population and supports use across primary care, telehealth, and specialty settings. The depression screening market benefits because validated tools become part of normal clinical delivery rather than an optional add-on.

CMS has finalized a Depression Screening and Follow-Up measure for Medicare Advantage Star Ratings beginning with the 2027 measurement year. The measure makes documented screening and follow-up more relevant to health plan quality programs. Health plans therefore have a reason to purchase tools that can support implementation and reporting. A questionnaire alone does not meet the full operational need when referral and care follow-up are not visible in the record. The depression screening market can gain from this change as payers look for validated digital systems that fit their quality processes. Providers also need referral capacity before increasing screening volume, which can delay some near-term purchases while supporting longer-term demand for integrated platforms.

EHR-Embedded Screening Accelerates Workflow Conversion Rates

Embedding standardized screening in electronic health records can make it easier to use within primary and preventive care. The PORTAL-Depression project showed how an EHR-integrated, computerized adaptive depression assessment could be implemented in primary care. This approach reduces the separation between completing a screen and recording its result in the clinical workflow. It also gives providers a clearer path to document referrals and treatment after a positive result. Research on adolescent digital screening found that primary care providers identified EHR integration gaps as a key adoption barrier. The depression screening market thus gives an advantage to vendors that support bidirectional data exchange and closed-loop follow-up.

EHR integration matters because the value of screening is measured by what happens after the score is recorded. Systems that link a result with referral coordination can improve the visibility of treatment initiation. This supports provider accountability where screening measures require follow-up. It also reduces the need for staff to move information between separate tools. The Depression screening industry can use this workflow position to compete on care delivery value rather than questionnaire delivery alone. App-only tools remain useful for some patient and employer programs, but they are less suited to clinical settings that require documented coordination.

Reimbursement Gaps Concentrate Risk at the Diagnostic Follow-Up Stage

Reimbursement is limited when a screening episode does not show diagnostic and follow-up capacity. The practical issue is not only whether a provider can administer a screen. It is whether the provider can document a suitable next step after a positive result. The new Medicare Advantage measure addresses this need, but implementation will take time. Some providers may build referral infrastructure before increasing screening volume. The depression screening market faces slower near-term platform revenue when providers cannot confidently deliver or record follow-up care.

Screening tools that include referral coordination and treatment initiation records have a stronger case with payers. This is because they support the clinical process that follows identification. One-time questionnaires can still be useful, but they face a weaker reimbursement position when they are disconnected from care delivery. Stigma and low patient engagement can further reduce completion and follow-up, particularly in some Asia-Pacific and Middle East and Africa settings. False positives can also strain referral systems when services are scarce. These barriers favor validated, clinically supported tools that can manage the full process from screening through treatment connection.

Other drivers and restraints analyzed in the detailed report include:

• Telehealth as the Default Screening Infrastructure for Scale
• AI Biomarker Analysis and Access for Underserved Populations
• Sensitive-Data Governance and Model Bias Constrain AI Adoption

Segment Analysis

Telehealth and Virtual Care Platforms held 44.31% of the depression screening market share within this segmentation in 2025. Their lead reflects telehealth adoption and the placement of PHQ-9, GAD-7, and EPDS tools into virtual care workflows. These platforms can place screening within an existing interaction and direct results to a clinician or care team without a separate workflow. Teladoc Health disclosed that more than 60 million members had access to its mental health services through health-plan and employer contracts in its 2025 annual report. This scale supports routine screening as a component of preventive virtual care.

Web-based screening platforms remain relevant for institutional programs and employer wellness delivery. Wearable and continuous-monitoring devices are earlier-stage options with limited clinical reimbursement, although they may become more relevant as biomarker evidence develops. AI-Based Screening Tools are forecast to grow at a 10.38% CAGR through 2031, which is the fastest pace in this segmentation. Ellipsis Health announced USD 45 million in funding in July 2025 alongside Sage, an AI care manager built on vocal biomarker technology. SonderMind launched an AI Suite in October 2025, while FDA software-as-a-medical-device pathways will increasingly influence which AI tools can compete for reimbursement.

Psychological Health Management accounted for 43.44% of the application segmentation in 2025. Its position reflects the broad use of ongoing symptom tracking, outcome measurement, and digital self-management tools. Employer-sponsored employee assistance programs and health-plan benefits commonly support continuous monitoring. These programs have a larger installed base than acute screening alone. Clinical Screening and Diagnosis Support provides the core questionnaire and AI-supported workflows used in care settings in the depression screening market.

Treatment Triage and Referral is forecast to grow at an 11.52% CAGR through 2031. The pace reflects the need to connect an identified concern with a documented care pathway. A 2025 study of a scalable e-mental-health intervention found reductions in depressive symptoms and supported structured care pathways that can prevent progression from subclinical to clinical major depressive disorder. Population and Epidemiological Screening is gaining use in government and institutional programs, including pilots in Japan and Germany. Other Applications include workplace wellness screening and school-based mental health assessment, where value rises when screening is linked to referral completion rather than treated as a one-time assessment.

Complete Report Scope:

• By Platform and Technology
  • Mobile Health Applications
  • Web-Based Screening Platforms
  • Telehealth and Virtual Care Platforms
  • AI-Based Screening Tools
  • Wearable and Continuous Monitoring Devices
  • Others
• By Application
  • Clinical Screening and Diagnosis Support
  • Psychological Health Management
  • Treatment Triage and Referral
  • Population and Epidemiological Screening
  • Other Applications
• By Care Setting
  • Hospitals and Clinics
  • Primary Care Practices
  • Specialty Mental Health Providers
  • Homecare Settings
  • Other Care Settings
• By Age Group
  • Children
  • Adolescents
  • Adults
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of the depression screening market share in 2025. The region combines routine use of USPSTF recommendations, employer-sponsored mental health benefits, and advanced digital mental health infrastructure. CMS is adding Depression Screening and Follow-Up to Medicare Advantage Star Ratings for the 2027 measurement year. This gives health plans a reason to invest in validated screening procurement and vendor relationships. The United States accounts for most regional revenue, while Canada and Mexico are growing through provincial systems and employer wellness programs.

Europe has national health-system integration paths, reimbursement mechanisms for digital health applications, and a more cautious approach to AI under GDPR. Germany’s DiGA framework provides a route for evidence-based digital health applications to be prescribed and reimbursed through statutory health insurance. France 2030 supported clinical validation of EmoCare, a multimodal platform using facial, voice, sleep, and activity data for continuous mood-disorder monitoring. The United Kingdom remains a growth market because of NHS-aligned digital mental health procurement, while Germany, the United Kingdom, and France account for the largest share of European revenue and Italy and Spain are expanding as national digital health plans prioritize mental health.

Asia-Pacific is forecast to grow at a 10.65% CAGR through 2031, the fastest regional pace in the depression screening market. China, Japan, India, Australia, and South Korea are expanding digital health infrastructure and mental health investment. Shortages of psychiatrists and psychologists, especially in India and Southeast Asia, support digital tools as initial access points rather than only additions to specialist care. South Korea is becoming an innovation center for voice and multimodal biomarker companies seeking clinical use in hospital systems. The Middle East and Africa and South America remain smaller regional opportunities, while GCC health transformation programs and employer-based tools in Brazil and Argentina support growing interest.

List of Companies Covered in this Report:

• Adaptive Testing Technologies
• Aiberry
• Apple
• Canary Speech, Inc.
• Clarigent Health
• Ellipsis Health, Inc.
• FuturesThrive
• Headspace
• Kintsugi Mindful Wellness, Inc.
• Koa Health
• Koninklijke Philips
• Limbic
• Lyra Health, Inc.
• Moodfit
• Proem Behavioral Health
• Quartet Health, Inc.
• Sonde Health
• SonderMind Inc.
• Teladoc Health
• Thymia Limited
• Woebot Health
• Wysa Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support